Form 4: ResMed Director Sells 2,000 Shares Under 10b5-1 Plan

ResMed Director Peter C. Farrell sold 2,000 shares of common stock for $251.31 per share, executed under a pre-arranged 10b5-1 plan.

Summary

• Peter C. Farrell, a Director of ResMed Inc. (RMD), reported a transaction involving the company's common stock.
• The transaction occurred on February 4, 2026, and involved the disposition of 2,000 shares.
• The shares were sold at a price of $251.31 per share.
• Following this transaction, Peter C. Farrell directly beneficially owns 64,773 shares of ResMed Common Stock.
• The sale was conducted pursuant to a Rule 10b5-1 plan, which was adopted on August 12, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event. While an insider sale typically carries a negative connotation, the execution under a pre-arranged 10b5-1 plan mitigates the immediate bearish signal, suggesting a planned financial move rather than a reaction to new adverse information.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a planned sale rather than a reaction to recent market events or non-public information, which enhances transparency and reduces the perception of opportunistic insider trading.

Negatives

• A director's sale of 2,000 shares, even if planned, represents a reduction in insider ownership, which can sometimes be interpreted by investors as a slightly negative signal regarding future stock performance or valuation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "/s/ Peter C. Farrell, Chairman emeritus" Signature confirming the accuracy of the reported transaction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by directors, are routinely monitored by investors for potential insights into management's perception of future stock performance. While a sale under a 10b5-1 plan is pre-scheduled and less indicative of immediate sentiment, it still represents a reduction in insider exposure to the company's equity.

Comparison to Industry Standards

• StockSavvy.ai notes that insider selling activity, especially by long-serving directors or executives, is a common occurrence across various industries as individuals manage personal financial planning, diversification, and liquidity needs. The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, providing a structured and transparent approach to insider trading, similar to practices observed at companies like Johnson & Johnson or Medtronic in the healthcare sector, where executives often utilize such plans for planned stock dispositions.

Corporate Governance

Related Party Transactions

• The disposition of 2,000 shares of ResMed Common Stock by Peter C. Farrell, a Director of the company, constitutes a related party transaction as it involves an insider of the issuer.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight reduction in management's direct equity interest, though the 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The insider sale, while a reduction in ownership, was executed under a pre-arranged 10b5-1 plan, which suggests a planned financial decision rather than a reaction to new company-specific information. This single transaction by a director does not fundamentally alter the investment thesis for ResMed, warranting a 'hold' recommendation as investors should focus on broader company fundamentals and market conditions.

Keywords

ResMed, RMD, Insider Sale, Form 4, Peter C. Farrell, 10b5-1 Plan, Director Transaction, Stock Sale